BG105751A - Използване на производни на 4-н-1-бензопиран-4-она като инхибитори на полиферацията на гладки мускулни клетки - Google Patents
Използване на производни на 4-н-1-бензопиран-4-она като инхибитори на полиферацията на гладки мускулни клеткиInfo
- Publication number
- BG105751A BG105751A BG105751A BG10575101A BG105751A BG 105751 A BG105751 A BG 105751A BG 105751 A BG105751 A BG 105751A BG 10575101 A BG10575101 A BG 10575101A BG 105751 A BG105751 A BG 105751A
- Authority
- BG
- Bulgaria
- Prior art keywords
- proliferation
- flavopiridol
- smc
- smooth muscle
- benzopyran
- Prior art date
Links
- 210000000329 smooth muscle myocyte Anatomy 0.000 title abstract 7
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 150000004777 chromones Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 abstract 4
- 229950010817 alvocidib Drugs 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 230000035755 proliferation Effects 0.000 abstract 4
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 230000003902 lesion Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 abstract 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 abstract 1
- 208000024248 Vascular System injury Diseases 0.000 abstract 1
- 208000012339 Vascular injury Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000008692 neointimal formation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 231100000216 vascular lesion Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Пролиферацията на гладките мускулни клетки (SMC) е критичен компонент на неоинтималната формация при много увреждания на кръвоносни съдове при животните и при човека. Инхибирането на клетъчния цикъл чрез техники на генен трансфер могат да блокират SMC пролиферацията и поразените формации при много животни, въпреки че тези методи все още не са приложими за лечение на заболявания на човека. Изобретението се отнася до ефектите на флавопиридола, наскоро идентифициран орално наличен циклин-зависим киназен инхибитор, върху растежа на SMC in vitro и in vivo. Флавопиридолът (75nmol/l) ефективно блокира пролиферацията на SMC-ефект, който е свързан с понижаването на циклин-зависимата киназна активност и свързаната с клетъчния цикъл експресия на гени. Изобретението се отнася и до ефектите на флавопиридола върху пролиферацията на SMC in vivo в моделна увреждане на сънна артерия на плъх. Флавопиридолът (5 mg/kg) понижава неоинтималния размер с 35%и 39% на 7-мия и на 14-тия ден, съответно, след балонно увреждане. Флавопиридолът може да бъде ефективно терапевтично средство за лечението на богатина SMC поражения на кръвоносните съдове. Производните на 4Н-1-бензопиран-4-она с обща формула инхибират пролиферацията на гладките мускулни клетки при ниски дози.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24338099A | 1999-02-01 | 1999-02-01 | |
| US09/468,665 US6399633B1 (en) | 1999-02-01 | 1999-12-21 | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG105751A true BG105751A (bg) | 2002-02-28 |
| BG65151B1 BG65151B1 (bg) | 2007-04-30 |
Family
ID=22918541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105751A BG65151B1 (bg) | 1999-02-01 | 2001-07-27 | Използване на производни на 4-н-1-бензопиран-4-она като инхибитори на пролиферацията на гладки мускулни клетки |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6399633B1 (bg) |
| EP (1) | EP1150746B1 (bg) |
| JP (1) | JP4755759B2 (bg) |
| KR (1) | KR100793047B1 (bg) |
| CN (1) | CN1219556C (bg) |
| AP (1) | AP1469A (bg) |
| AR (1) | AR042569A1 (bg) |
| AT (1) | ATE275428T1 (bg) |
| AU (1) | AU777368B2 (bg) |
| BG (1) | BG65151B1 (bg) |
| BR (1) | BR0007911A (bg) |
| CA (1) | CA2360668C (bg) |
| CR (1) | CR6448A (bg) |
| CZ (1) | CZ300395B6 (bg) |
| DE (1) | DE60013555T2 (bg) |
| DK (1) | DK1150746T3 (bg) |
| EA (1) | EA004786B1 (bg) |
| EE (1) | EE04851B1 (bg) |
| ES (1) | ES2226792T3 (bg) |
| HK (1) | HK1042445B (bg) |
| HR (1) | HRP20010521A2 (bg) |
| HU (1) | HU229263B1 (bg) |
| ID (1) | ID30180A (bg) |
| IL (1) | IL144668A (bg) |
| ME (1) | MEP10508A (bg) |
| NO (1) | NO330512B1 (bg) |
| NZ (1) | NZ512822A (bg) |
| OA (1) | OA11755A (bg) |
| PL (1) | PL197693B1 (bg) |
| PT (1) | PT1150746E (bg) |
| RS (1) | RS50242B (bg) |
| SI (1) | SI1150746T1 (bg) |
| SK (1) | SK286747B6 (bg) |
| TR (1) | TR200102223T2 (bg) |
| TW (1) | TWI273907B (bg) |
| UA (1) | UA73110C2 (bg) |
| WO (1) | WO2000044362A2 (bg) |
| ZA (1) | ZA200105596B (bg) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
| KR101052816B1 (ko) * | 2002-04-17 | 2011-07-29 | 스미스 클라인 비참 코포레이션 | 화합물, 조성물 및 방법 |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040082613A1 (en) * | 2002-06-28 | 2004-04-29 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| US20040106647A1 (en) * | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 ｉｌ?９ 항체 및 그의 용도 |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| WO2005042743A2 (en) | 2003-08-18 | 2005-05-12 | Medimmune, Inc. | Humanization of antibodies |
| AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| JP5153613B2 (ja) | 2005-03-18 | 2013-02-27 | メディミューン，エルエルシー | 抗体のフレームワーク・シャッフル |
| CA2613512A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| CA2617728A1 (en) * | 2005-07-15 | 2007-01-25 | Sahajanand Biotech Private Limited | Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis |
| JP2008255008A (ja) * | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| AU2006275514B2 (en) * | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| MY162024A (en) | 2006-08-28 | 2017-05-31 | La Jolla Inst Allergy & Immunology | Antagonistic human light-specific human monoclonal antibodies |
| CN101641339B (zh) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
| EP2068923A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| MX2021012876A (es) | 2009-03-18 | 2022-06-23 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| ES2821018T3 (es) | 2009-04-22 | 2021-04-23 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
| WO2012007327A1 (en) | 2010-07-12 | 2012-01-19 | Dkfz Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
| EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
| BR112015001459B1 (pt) | 2012-07-25 | 2023-02-14 | Celldex Therapeutics, Inc | Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo |
| WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| RU2699289C2 (ru) | 2013-08-26 | 2019-09-04 | Байонтек Рисерч Энд Дивелопмент, Инк. | НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AU2015271685B2 (en) | 2014-06-04 | 2021-02-18 | Biontech Research And Development, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| US10766959B2 (en) | 2014-12-11 | 2020-09-08 | Pierre Fabre Medicament | Anti-C10ORF54 antibodies and uses thereof |
| CN114504652A (zh) | 2015-03-03 | 2022-05-17 | 科马布有限公司 | 抗体、用途和方法 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| US9758539B2 (en) | 2015-05-18 | 2017-09-12 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
| CN108289861B (zh) | 2015-08-03 | 2021-11-02 | 大日本住友制药肿瘤公司 | 用于治疗癌症的组合疗法 |
| EP3383908A1 (en) | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator) |
| EP3909983A1 (en) | 2015-12-02 | 2021-11-17 | STCube & Co. Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| CN109803684B (zh) | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP7219224B2 (ja) | 2017-03-16 | 2023-02-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 乳癌の治療のための組合せ療法 |
| JP2020522512A (ja) | 2017-05-31 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法 |
| JP7369038B2 (ja) | 2017-05-31 | 2023-10-25 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
| AU2019306165A1 (en) | 2018-07-20 | 2021-02-25 | Pierre Fabre Medicament | Receptor for vista |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| CN113559244B (zh) * | 2021-08-02 | 2023-12-26 | 华中科技大学同济医学院附属协和医院 | Ctrp13脂肪因子的新用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (bg) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
| JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン |
-
1999
- 1999-12-21 US US09/468,665 patent/US6399633B1/en not_active Expired - Fee Related
-
2000
- 2000-01-18 AT AT00909918T patent/ATE275428T1/de active
- 2000-01-18 PL PL350735A patent/PL197693B1/pl not_active IP Right Cessation
- 2000-01-18 IL IL14466800A patent/IL144668A/xx not_active IP Right Cessation
- 2000-01-18 SI SI200030517T patent/SI1150746T1/xx unknown
- 2000-01-18 OA OA1200100196A patent/OA11755A/en unknown
- 2000-01-18 CN CNB008032513A patent/CN1219556C/zh not_active Expired - Fee Related
- 2000-01-18 SK SK1086-2001A patent/SK286747B6/sk not_active IP Right Cessation
- 2000-01-18 CZ CZ20012804A patent/CZ300395B6/cs not_active IP Right Cessation
- 2000-01-18 AP APAP/P/2001/002218A patent/AP1469A/en active
- 2000-01-18 ID IDW00200101696A patent/ID30180A/id unknown
- 2000-01-18 AU AU32098/00A patent/AU777368B2/en not_active Ceased
- 2000-01-18 DK DK00909918T patent/DK1150746T3/da active
- 2000-01-18 WO PCT/US2000/001104 patent/WO2000044362A2/en active IP Right Grant
- 2000-01-18 CA CA002360668A patent/CA2360668C/en not_active Expired - Fee Related
- 2000-01-18 ME MEP-105/08A patent/MEP10508A/xx unknown
- 2000-01-18 HU HU0200804A patent/HU229263B1/hu not_active IP Right Cessation
- 2000-01-18 NZ NZ512822A patent/NZ512822A/en not_active IP Right Cessation
- 2000-01-18 JP JP2000595666A patent/JP4755759B2/ja not_active Expired - Fee Related
- 2000-01-18 BR BR0007911-1A patent/BR0007911A/pt not_active Application Discontinuation
- 2000-01-18 DE DE60013555T patent/DE60013555T2/de not_active Expired - Lifetime
- 2000-01-18 EE EEP200100385A patent/EE04851B1/xx not_active IP Right Cessation
- 2000-01-18 TR TR2001/02223T patent/TR200102223T2/xx unknown
- 2000-01-18 KR KR1020017009716A patent/KR100793047B1/ko not_active IP Right Cessation
- 2000-01-18 UA UA2001075481A patent/UA73110C2/uk unknown
- 2000-01-18 ES ES00909918T patent/ES2226792T3/es not_active Expired - Lifetime
- 2000-01-18 RS YU54401A patent/RS50242B/sr unknown
- 2000-01-18 EA EA200100742A patent/EA004786B1/ru not_active IP Right Cessation
- 2000-01-18 PT PT00909918T patent/PT1150746E/pt unknown
- 2000-01-18 EP EP00909918A patent/EP1150746B1/en not_active Expired - Lifetime
- 2000-01-25 TW TW089101215A patent/TWI273907B/zh not_active IP Right Cessation
- 2000-02-01 AR ARP000100420A patent/AR042569A1/es not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013335A patent/NO330512B1/no not_active IP Right Cessation
- 2001-07-06 ZA ZA200105596A patent/ZA200105596B/en unknown
- 2001-07-11 HR HR20010521A patent/HRP20010521A2/hr not_active Application Discontinuation
- 2001-07-27 BG BG105751A patent/BG65151B1/bg unknown
- 2001-08-23 CR CR6448A patent/CR6448A/es not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104062.3A patent/HK1042445B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105751A (bg) | Използване на производни на 4-н-1-бензопиран-4-она като инхибитори на полиферацията на гладки мускулни клетки | |
| MX2007003321A (es) | Derivados heterociclicos y su uso como agentes terapeuticos. | |
| TW200516149A (en) | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair | |
| TW200624427A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626139A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626148A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626154A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626153A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TNSN06032A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| MX2007003327A (es) | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. | |
| IL172705A0 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases | |
| TW200626155A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TNSN06034A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| MXPA05010899A (es) | Derivados de 2-aminopirimidina y su uso medico. | |
| HK1021699A1 (en) | Pentafluorobenzenesulfonamides and analogs. | |
| MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
| BRPI0410649A (pt) | benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k | |
| EP1485096A4 (en) | METHODS FOR PREVENTING OR TREATING HEART ARRHYTHMIA | |
| MY134562A (en) | Methods and compositions to treat conditions associated with neovascularization | |
| WO2003082861A3 (en) | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases | |
| WO2000047231A3 (en) | Novel antisense inhibition of rad51 | |
| MY144229A (en) | Pyridazine derivatives and their use as therapeutic agents | |
| AU2002222225A1 (en) | Substituted-4-quinolones | |
| HK1045150A1 (zh) | 類鴉片化合物 |